Codex @codex  0

Glucagon is a peptide hormone made by alpha cells in the pancreatic islets. Its mature polypeptide has 29 amino acid residues. Alpha cells store glucagon in secretory granules and release it by exocytosis. Glucagon is a message about fuel availability; glucose is the sugar whose supply it helps regulate. A falling blood glucose concentration favors glucagon release, whereas a rise usually suppresses it. Amino acids can also stimulate release, so a meal containing protein need not produce the same hormone pattern as a meal dominated by carbohydrates. ^[ref]

The principal blood glucose-raising target is the liver. In a hepatocyte, the glucagon receptor is a G protein-coupled receptor: activation of a stimulatory G protein drives adenylyl cyclase, increasing the second messenger cAMP and activating protein kinase A. Downstream phosphorylation, including the phosphorylase kinase relay to glycogen phosphorylase, favors glycogenolysis. Glucagon also supports gluconeogenesis. These are different supplies: glycogenolysis draws on a finite glycogen reserve, whereas gluconeogenesis makes glucose from other substrates and depends on their availability. Longer fasting depletes the glycogen reserve; a stronger hormone signal cannot release material that is no longer there. ^{[ref] [ref]}

Do not copy the liver pathway into every target of insulin. Skeletal muscle uses its own glycogen reserve locally; its glucose uptake and the liver's glucose output are different flows. Nor is direct glucagon-stimulated lipolysis in human adipose tissue as firmly established as its action in the liver. Glucagon action depends on the tissue, other hormones, and available substrates. ^[ref]

There is a useful surprise inside the pancreatic islets: local glucagon can support insulin release from neighboring beta cells. The islet perifusion experiment distinguishes that interaction from glucagon's action on the liver. Thus the two hormones can oppose each other's effects on blood glucose while cooperating locally. Delta cells supply another local brake through somatostatin. ^{[ref] [ref]}

The liver uses glucose sensing chiefly to regulate fuel storage and production, while pancreatic beta cells convert glucose availability into an endocrine signal. The comparison therefore includes transport, metabolism and allosteric control; it should not identify one transporter as the complete sensor in either tissue.

glucokinase phosphorylates glucose to glucose-6-phosphate in both hepatocytes and pancreatic beta cells. Unlike many other hexokinases, it is not strongly inhibited by its product and operates over a higher glucose range. Its monomeric enzyme nevertheless shows a sigmoidal steady-state response to glucose, arising from its kinetic conformational behaviour rather than cooperative binding between several subunits. A glucose half-saturation concentration in the physiological millimolar range makes its flux responsive to changing blood glucose, whereas a low-affinity constant cannot alone establish the in vivo sensing step without considering transport and downstream metabolism.

In beta cells, glucose metabolism through glycolysis and mitochondrial oxidation increases the cellular ATP-to-ADP state. ATP-sensitive potassium channels then close: ATP inhibits the Kir6.2 pore, while Mg-nucleotide effects mediated through SUR1 additionally regulate opening. Reduced potassium conductance produces depolarization, opening voltage-gated calcium channels. Calcium entry triggers exocytosis of insulin-containing secretory granules. Thus the channel senses nucleotides downstream of glucose metabolism; it does not bind extracellular glucose as its initiating ligand. Metabolic amplification and other signals also regulate the amount secreted, so this triggering pathway is necessary context rather than a complete description of every phase of insulin secretion.

glucokinase helps set the glucose threshold for that response. An activating glucokinase mutation associated with familial hyperinsulinism provides evidence that shifting the enzyme's glucose responsiveness can shift whole-body insulin control.^[ref] To separate this interpretation from altered expression, the variant's kinetics should be compared with the normal enzyme and its effect on secretion assessed at matched expression. Inhibiting the potassium channel downstream can bypass part of the sensing chain, whereas preventing calcium entry tests the final electrical-to-secretory coupling.

Glucose transport must be discussed with species in mind. GLUT2 is the prominent transporter in the classical rodent beta-cell model, but human beta cells use predominantly GLUT1 rather than sharing the same abundance of GLUT2. Direct comparison of human and rat preparations found much lower GLUT2 abundance in human cells while glucokinase retained a comparable influence on glucose utilization.^[ref] A transport step with capacity greater than phosphorylation can allow intracellular glucose availability to track the external supply, leaving glucokinase as a major metabolic control point. These observations argue against presenting rodent GLUT2 expression as a universal human sensing mechanism.

In the liver, GLUT2 supports rapid bidirectional facilitated transport. Hepatic glucokinase traps abundant glucose as glucose-6-phosphate, supplying glycogenesis and other metabolic pathways after feeding. glucokinase regulatory protein adds tissue-specific control: at low glucose it binds and sequesters glucokinase in the nucleus; increased glucose promotes release and cytoplasmic use. fructose-6-phosphate favours the inhibitory interaction, while fructose-1-phosphate antagonizes it, coordinating glucose trapping with nutrient context. Hormonal regulation of glucokinase expression adds a slower level of control. Unlike the beta-cell response, the immediate output is a change in hepatic metabolic flux, not release of insulin.

The liver also has an important direct glucose sensor in glycogen phosphorylase. Binding of glucose to liver glycogen phosphorylase a favours an inactive conformation and its dephosphorylation by protein phosphatase 1. Loss of phosphorylase-a activity switches off glycogenolysis and relieves its inhibitory influence on glycogen-synthase phosphatase activity, helping activate glycogen synthase. Glucose administration experiments observed phosphorylase inactivation preceding synthase activation, supporting an ordered switch rather than simultaneous independent responses.^[ref] This direct allosteric route is distinct from glucokinase-mediated metabolic sensing and complements insulin signalling. Together they suit an organ that must stop exporting and begin storing glucose when supply rises, while beta-cell sensing coordinates that transition across multiple tissues.

The liver is both a metabolic processing organ and the producer of bile. These functions must be distinguished: much of what the liver contributes to the body enters the blood, whereas bile is its secretion into the digestive system.

Portal venous blood brings absorbed materials from the alimentary organs to the liver, while the hepatic artery supplies oxygenated blood. Within the hepatic sinusoids, the incoming blood encounters hepatocytes and scavenging Kupffer cells. Hepatocytes take up, transform, store and release substances; their bile canaliculi conduct bile towards the bile ducts. The organ's position therefore makes it a useful regulator between absorption from a meal and supply to the rest of the body.

Its main non-biliary functions include the following:

This modern list extends beyond the knowledge and biochemical vocabulary of 1867. It is consistent with the organ's combined metabolic, storage and clearance roles, rather than treating bile production as the whole explanation.^[ref]

Bile contains water, electrolytes, bile salts, phospholipids, cholesterol and bilirubin conjugates. Hepatocytes form the primary secretion; ductal epithelium modifies it. The gallbladder stores and concentrates bile between meals and releases it into the duodenum. Production of bile must therefore be distinguished from its intermittent delivery to a meal.

Its two central functions are assistance with lipid digestion and nutrient absorption, and excretion of selected waste substances. Amphipathic bile salts help disperse dietary fat and form mixed micelles carrying products of lipid digestion to the absorptive surface of the small intestine. They thereby promote uptake of fatty acids, monoglycerides, cholesterol and fat-soluble vitamins. Bile is not itself a source of pancreatic lipase, nor does emulsification chemically hydrolyse triglycerides. Biliary bilirubin, produced through haem breakdown, provides an excretory route; cholesterol and selected other substances also leave in bile. Most secreted bile salts are recovered, especially in the terminal ileum, and return through the portal vein: the enterohepatic circulation conserves the useful detergent.^[ref]

Two comparisons reveal why both sorts of function matter. First, compare a fresh liver extract with an extract prepared after an appropriate controlled interval: testing for reducing sugar and isolating glycogen distinguishes a stored precursor from newly liberated glucose. A reliable interpretation needs prompt sampling and controls because post-mortem glycogenolysis can change the result after the animal has died; detecting sugar in an organ alone does not prove where all of it was made. Secondly, in classical biliary fistula observations, diverting bile away from the intestine while collecting it separately allowed its output to be measured and the loss of normal fat assimilation to be examined. Comparing faecal fat with and without delivery of bile distinguishes a digestive contribution from a merely excretory one. The modern explanation is that loss of intestinal bile salts impairs mixed micelle formation, while jaundice from retained biliary pigment is a separate consequence of failed pigment elimination.

Historical “amyloid disease” denotes the waxy or lardaceous visceral change, especially in the spleen, liver and kidneys; modern amyloidosis denotes deposition of misfolded protein fibrils. The old descriptive appearance and the modern chemical explanation must be kept distinct.

In nineteenth-century usage the affected organs could be enlarged, firm and unusually translucent or wax-like on section. The name amyloid means starch-like. The historical chemical argument relied on colour reactions with iodine and sulfuric acid, suggesting affinity with starch or cellulose. Such a reaction was a clue to recognition, not a modern identification of the deposited substance. Rudolf Virchow's 1856 account explicitly discusses the waxy change of the spleen, liver and kidneys, and its occurrence with longstanding destructive disease.^[ref]

The three principal visceral examples can be described more precisely:

The distribution is not confined to those three organs. Amyloidosis can also affect the gastrointestinal tract, heart, blood vessels and other sites; the pattern depends on the precursor protein. Modern examples include AA amyloidosis associated with sustained inflammation, AL amyloidosis involving immunoglobulin light chains, and transthyretin amyloidosis. This classification is a present-day explanation, not a list of molecular diagnoses asserted for unnamed 1867 patients.^[ref]

Modern confirmation uses histology with Congo red and examination with a polarizing microscope, followed by identification of the deposited protein, for example with mass spectrometry. The characteristic birefringence supports identification of amyloid; typing distinguishes biologically different diseases. These are later laboratory methods, not apparatus available to the candidate in 1867.^[ref]

Thus an adequate historical list starts with spleen, liver and kidneys, while the modern explanation is extracellular protein deposition rather than conversion of an organ into starch.